NIM 1324
Alternative Names: BT-104; LABP-104; NIM-1324Latest Information Update: 19 Feb 2026
At a glance
- Originator Landos Biopharma
- Class Anti-inflammatories; Antirheumatics; Small molecules; Urologics
- Mechanism of Action Inflammation mediator inhibitors; LANCL2 protein stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 19 Feb 2026 NIM 1324 is still in phase I development in Rheumatoid-arthritis (In volunteers, In adults) in Australia (PO) (NImmune Biopharma pipeline, February 2026)
- 19 Feb 2026 Phase-I clinical trials in Lupus nephritis in USA (PO) (NImmune Biopharma pipeline, February 2026)
- 17 Feb 2026 NImmune Biopharma plans a phase II trial for ulcerative colitis and Crohn’s disease